Ginger dry extract 200 mg three times daily for three months,
does it really help with Prevention of episodic migraine in adults?
research showsGrade D with 30 points. In a double-blind randomized trial of 107 adults, ginger dry extract 200 mg three times daily for three months did not increase the proportion achieving at least a 50% reduction in migraine attacks versus placebo. Severe-pain days, acute analgesic use, and attack duration also showed no between-group advantage.
ads claimThe claim that ginger prevents migraine because it may affect nausea transfers evidence from other symptoms, combination products, or acute treatment to long-term monotherapy.
Useful facts when choosing a product
- This was a three-month prevention trial, not acute-attack treatment.
- It differs from feverfew-plus-ginger combinations.
- Culinary ginger doses are not interchangeable with the standardized 200-mg extract.
What the research actually shows
Participants took 200 mg of dry ginger extract standardized to 5% active constituents three times daily for three months versus placebo.
Why this is classified as D (30)
Double blinding and a placebo control are strengths, but the core between-group results were null in the sole direct trial, giving D with 30 points.
Counterpoint. Incomplete precision and no externally anchored benefit threshold prevent claiming proof of zero effect.
Rejudgment record. Cross-check applied — Centered the 50% responder and all core between-group comparisons and excluded within-group change, acute combinations, and active-control studies
| Endpoint | P | Patient-reported treatment goal - the symptom is the goal |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E0 | Null |
| Precision | C0 | The confidence interval leaves room for benefit |
The scoring table and the verdict agree (D).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| At least 50% reduction in migraine attacks | D | There was no significant difference from placebo. |
| Reduced severe-pain days, acute analgesic use, or attack duration | D | Within-group changes occurred without a between-group advantage. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Double-blind placebo-controlled randomized trial | 107 | Independent of a manufacturer in the publication; support details checked in full text | 50% attack responder rate, severe-pain days, analgesic use, and duration | No significant between-group difference in the core outcomes | Only direct prevention trial |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-09-07).
Final verification and publication gate: Codex · Verification cutoff: 2026-09-07 · Corrections: none
Cite this verdict
[Chamgap] Ginger Dry Extract for Migraine Prevention—No Added Benefit in a Three-Month Placebo-Controlled Trial — Evidence Grade D·30. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/cognition/ginger-dry-extract-episodic-migraine-prevention-three-months/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.